An observational study in Alpha-Mannosidosis, sponsored by Chiesi Farmaceutici S.p.A.. Recruiting at 2 sites in United States. Open to participants aged Up to 3 Years. Per ClinicalTrials.gov, last updated 2025-05-16.
Sponsored by Chiesi Farmaceutici S.p.A. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. — 1 open to participants now, 1 under way, none of them phase 3. alpha-Mannosidosis · Chiesi Farmaceutici S.p.A..
Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., this one is the only one that started in 2025, is one of 2 observational ones, and was the 12th registered.
24 studies on the registry are indexed under alpha-Mannosidosis; 6 are open to participants now.
Browse alpha-Mannosidosis studies →1 of the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A. is open now, in 1 country.
By country, each count listing its studies:
Of the 5 alpha-Mannosidosis studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; none take healthy volunteers.
This study: Up to 3 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2025.
Median enrollment 10 across the 9 interventional studies, 25 across the 2 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Chiesi Farmaceutici S.p.A. is the lead sponsor of 185 studies on the registry; 22 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 11 (61%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 12 studies in alpha-Mannosidosis by Chiesi Farmaceutici S.p.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this observational study is to learn the effects of the drug velmanase alfa (Lamzede®) in the bodies of children under the age of 3 with Alpha-Mannosidosis.
The main questions it aims to answer are:
Additional data will be extracted from other observational sponsored studies/registries, compassionate use programs, investigator-initiated studies (IIS), and published case reports (presented in the literature) if existing.
Paediatric patients with a confirmed diagnosis of alpha mannosidosis via MAN2B1 genetic testing and/or alpha-mannosidase activity in leukocytes or fibroblasts \< 10% of normal activity, with data for at least one pre- and one post-Lamzede treatment sample obtained when \< 3 YOA, after at least 6 weeks of treatment (primary analyses).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
before velmanase treatment initiation (ideally max 6 month before), and at least one post-treatment sample, collected following at least six weeks of treatment.
Exclusion Criteria:
Participants who have undergone prior hematopoietic stem cell transplantation () or other therapies for treating alfa mannosidosis (supportive treatments acceptable).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Paediatric patients with a confirmed diagnosis of alpha-mannosidosis with data for at least one pre- and one post-Lamzede treatment sample obtained when \< 3 YOA.
Drug: Velmanase Alfa
Lamzede® (velmanase alfa, henceforth referred to as Lamzede) is a recombinant human lysosomal alpha-mannosidase product developed as an intravenous enzyme replacement therapy (ERT) for the treatment of alpha-mannosidosis.
Also known as: Lamzede
Pharmacodynamic Response to velmanase alfa
Change (absolute and relative) of GlcNAc(Man)2 level from pre-velmanase alfa treatment baseline in blood
Time frame: 52 weeks of treatment
Development of anti drug antibody to velmanase alfa
Assessment of the impact of anti drug antibody on pharmacodinamic
Time frame: 52 weeks of treatment
Treatment-emergent adverse events
Number of undesirable events not present prior to medical treatment, or an already present event that worsens either in intensity or frequency following the treatment
Time frame: 52 weeks
Plan to share: No
Started Feb 2025 (actual). Primary completion is estimated for Sep 2029, 55 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.